/IVME

IVME Stock - In Veritas Medical Diagnostics, Inc.

Q: What is the analyst price target for IVME?

Analyst price target information is not currently available for IVME.

Q: What is IVME's market cap?

Market capitalization information is not currently available for IVME.

Financial Services|Shell Companies|OTC

$0.00-99.77%

$0.30 (-99.77%) • Aug 5

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IVME

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2004

FY2005

FY2006

FY2007

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta7.80

52W High$0.30

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2007	FY2006	FY2005	FY2004
Revenue	N/A	N/A	$1.27M	$879,847	$760,516
Gross Profit	N/A	N/A	$1.27M	$875,267	$759,693
Gross Margin	N/A	N/A	100.0%	99.5%	99.9%
Operating Income	$-107,800	$2.72M	$959,060	$2.27M	$1.01M
Net Income	$-107,800	$-3,670,764	$-1,848,797	$-2,450,792	$734,544
Net Margin	N/A	N/A	-145.4%	-278.5%	96.6%
EPS	$-0.00	$-0.06	$-0.03	$-0.05	$-0.09

Company Overview

In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.

Frequently Asked Questions about IVME

What is IVME's current stock price?

In Veritas Medical Diagnostics, Inc. (IVME) is currently trading at $0.00 per share. The stock has moved -99.77% today.

What is the analyst price target for IVME?

No analyst price targets are currently available for this stock.

What sector is In Veritas Medical Diagnostics, Inc. in?

In Veritas Medical Diagnostics, Inc. operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the OTC exchange.

What is IVME's market cap?

In Veritas Medical Diagnostics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does IVME pay dividends?

No, In Veritas Medical Diagnostics, Inc. does not currently pay a dividend to shareholders.